The delivery of the FMR1 gene and its product to animal models of FXS have been primarily conducted with intrathecal applications because of the low efficiency of the gene therapy vectors to cross the blood–brain barrier (BBB). The gene discussed is FMR1; the disease is fragile X syndrome.